Literature DB >> 18554148

The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury.

Jun-ichi Suzuki1, Masahito Ogawa, Susumu Muto, Yoichi Yamaguchi, Akiko Itai, Mitsuaki Isobe.   

Abstract

OBJECTIVE: Plasminogen activator inhibitor (PAI)-1 plays a role in neointimal formation after percutaneous coronary intervention (PCI), the effect of overexpression or lack of PAI-1 is controversial. Murine arterial injury models develop neointimal hyperplasia similar to that observed in clinical coronary arterial restenosis after PCI. METHODS AND
RESULTS: To clarify the role of PAI-1 in thrombus formation and neointimal formation after arterial injury, we used a specific PAI-1 inhibitor (IMD-1622) in a rat aorta-vein shunt model and a mouse arterial injury model. While the non-treated shunt model showed massive thrombus formation, IMD-1622 administration suppressed this. Injured arteries with vehicles showed significant neointimal formation with enhancement of adhesion molecules, fibrinogen accumulation and cell proliferation on day 28 after injury. However, intimal thickening and expression of these factors were suppressed in PAI-1 recipients.
CONCLUSION: A specific PAI-1 inhibitor prevents thrombus formation and arterial neointimal formation after arterial injury. Thus, PAI-1 plays a critical role in arterial remodeling after mechanical injury. PAI-1 regulation may be useful to prevent thrombus and neointimal formation after PCI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18554148     DOI: 10.1517/14728222.12.7.783

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

1.  Angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Lidiana D Almeida-Paula; Joseph W Harding; D Neil Granger
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

2.  Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.

Authors:  Stephanie Brandal; Charlene M Blake; Bruce A Sullenger; Yolanda M Fortenberry
Journal:  Nucleic Acid Ther       Date:  2011-11-21       Impact factor: 5.486

Review 3.  Restenosis after PCI. Part 1: pathophysiology and risk factors.

Authors:  J Wouter Jukema; Jeffrey J W Verschuren; Tarek A N Ahmed; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-09-13       Impact factor: 32.419

4.  Porphyromonas gingivalis promotes neointimal formation after arterial injury through toll-like receptor 2 signaling.

Authors:  Naho Kobayashi; Jun-ichi Suzuki; Masahito Ogawa; Norio Aoyama; Issei Komuro; Yuichi Izumi; Mitsuaki Isobe
Journal:  Heart Vessels       Date:  2013-09-04       Impact factor: 2.037

5.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

6.  Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.

Authors:  Tessa M Simone; Stephen P Higgins; Craig E Higgins; Michelle R Lennartz; Paul J Higgins
Journal:  J Mol Genet Med       Date:  2014-10

Review 7.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

8.  Effect of TGF-β1 on the Migration and Recruitment of Mesenchymal Stem Cells after Vascular Balloon Injury: Involvement of Matrix Metalloproteinase-14.

Authors:  Wei Zhao; Chengyan Wang; Ruixue Liu; Cuilei Wei; Juncang Duan; Kejian Liu; Shugang Li; Hong Zou; Jin Zhao; Lianghai Wang; Yan Qi; Weihua Liang; Jinfang Jiang; Wenjie Zhang; Lijuan Pang; Feng Li
Journal:  Sci Rep       Date:  2016-02-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.